IL285050A - Administering PD-1 inhibitors for the treatment of skin cancer - Google Patents
Administering PD-1 inhibitors for the treatment of skin cancerInfo
- Publication number
- IL285050A IL285050A IL285050A IL28505021A IL285050A IL 285050 A IL285050 A IL 285050A IL 285050 A IL285050 A IL 285050A IL 28505021 A IL28505021 A IL 28505021A IL 285050 A IL285050 A IL 285050A
- Authority
- IL
- Israel
- Prior art keywords
- inhibitors
- administration
- skin cancer
- treating skin
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962811827P | 2019-02-28 | 2019-02-28 | |
| PCT/US2020/020018 WO2020176699A1 (en) | 2019-02-28 | 2020-02-27 | Administration of pd-1 inhibitors for treating skin cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL285050A true IL285050A (en) | 2021-09-30 |
Family
ID=70057261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL285050A IL285050A (en) | 2019-02-28 | 2021-07-22 | Administering PD-1 inhibitors for the treatment of skin cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220259313A1 (https=) |
| EP (1) | EP3930848A1 (https=) |
| JP (2) | JP2022521800A (https=) |
| KR (1) | KR20210134690A (https=) |
| CN (1) | CN113490529A (https=) |
| AU (1) | AU2020228296B2 (https=) |
| CA (1) | CA3137361A1 (https=) |
| IL (1) | IL285050A (https=) |
| MA (1) | MA55084A (https=) |
| MX (1) | MX2021010228A (https=) |
| SG (1) | SG11202108089SA (https=) |
| WO (1) | WO2020176699A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| JP7126941B2 (ja) | 2015-12-22 | 2022-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ |
| US12516382B2 (en) | 2018-12-07 | 2026-01-06 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method of determining risk for skin cancer development and skin cancer therapeutic prevention by measuring PD-1/PD-L1 signaling pathway members |
| KR20230141869A (ko) * | 2021-02-11 | 2023-10-10 | 리제너론 파마슈티칼스 인코포레이티드 | 신보조 요법으로서 pd-1 저해제의 투여에 의한 암 치료 방법 |
| WO2024186917A2 (en) * | 2023-03-06 | 2024-09-12 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions for pd-l1 inhibition and methods of use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| JP6240600B2 (ja) | 2011-07-24 | 2017-11-29 | キュアテク リミテッド | ヒト化免疫モノクローナル抗体の変異体 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| WO2013181452A1 (en) | 2012-05-31 | 2013-12-05 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| HK1204557A1 (en) | 2012-05-31 | 2015-11-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| US10435470B2 (en) | 2014-08-05 | 2019-10-08 | Cb Therapeutics, Inc. | Anti-PD-L1 antibodies |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| WO2017106656A1 (en) * | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| JP7126941B2 (ja) * | 2015-12-22 | 2022-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ |
| CN109310677A (zh) | 2016-04-07 | 2019-02-05 | 凯莫森特里克斯股份有限公司 | 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷 |
| TWI755395B (zh) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| KR20240011262A (ko) * | 2017-02-21 | 2024-01-25 | 리제너론 파아마슈티컬스, 인크. | 폐암의 치료를 위한 항-pd-1 항체 |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| AU2018287317B2 (en) * | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
-
2020
- 2020-02-27 MA MA055084A patent/MA55084A/fr unknown
- 2020-02-27 WO PCT/US2020/020018 patent/WO2020176699A1/en not_active Ceased
- 2020-02-27 AU AU2020228296A patent/AU2020228296B2/en active Active
- 2020-02-27 SG SG11202108089SA patent/SG11202108089SA/en unknown
- 2020-02-27 KR KR1020217030808A patent/KR20210134690A/ko active Pending
- 2020-02-27 MX MX2021010228A patent/MX2021010228A/es unknown
- 2020-02-27 EP EP20715554.0A patent/EP3930848A1/en active Pending
- 2020-02-27 JP JP2021550167A patent/JP2022521800A/ja active Pending
- 2020-02-27 CA CA3137361A patent/CA3137361A1/en active Pending
- 2020-02-27 US US17/433,003 patent/US20220259313A1/en active Pending
- 2020-02-27 CN CN202080017060.8A patent/CN113490529A/zh active Pending
-
2021
- 2021-07-22 IL IL285050A patent/IL285050A/en unknown
-
2024
- 2024-12-20 JP JP2024225122A patent/JP2025041768A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3930848A1 (en) | 2022-01-05 |
| WO2020176699A1 (en) | 2020-09-03 |
| JP2025041768A (ja) | 2025-03-26 |
| SG11202108089SA (en) | 2021-08-30 |
| AU2020228296A1 (en) | 2021-10-14 |
| US20220259313A1 (en) | 2022-08-18 |
| KR20210134690A (ko) | 2021-11-10 |
| CA3137361A1 (en) | 2020-09-03 |
| CN113490529A (zh) | 2021-10-08 |
| JP2022521800A (ja) | 2022-04-12 |
| MA55084A (fr) | 2022-01-05 |
| AU2020228296B2 (en) | 2025-10-02 |
| MX2021010228A (es) | 2021-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285050A (en) | Administering PD-1 inhibitors for the treatment of skin cancer | |
| IL287838A (en) | Kras inhibitor dosage for cancer treatment | |
| IL308195A (en) | RAS inhibitors for cancer treatment | |
| IL284324A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
| IL284326A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
| SG10202011110PA (en) | Methods of treating skin cancer by administering a pd-1 inhibitor | |
| SG11202104923YA (en) | Pharmaceutical combination for treatment of cancer | |
| EP4010081A4 (en) | POLYTHERAPY FOR THE TREATMENT OF CANCER | |
| CA3255651A1 (en) | Multispecific agents for treatment of cancer | |
| AU2019383310B2 (en) | Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers | |
| GB201913030D0 (en) | Treatment of hr deficient cancer | |
| IL274198A (en) | Use of Nox inhibitors to treat cancer | |
| EP3856352A4 (en) | Methods of treatment of cancer comprising cdc7 inhibitors | |
| IL316829A (en) | Menin-MLL inhibitors for cancer treatment | |
| SI3880186T1 (sl) | Intralezijska uporaba zaviralcev PD-1 za zdravljenje kožnega raka | |
| IL289201A (en) | Compounds for the treatment of cancer | |
| EP3758678A4 (en) | METHODS OF TREATMENT OF CANCER WITH CHK1 INHIBITORS | |
| PT3630112T (pt) | Combinação de regorafenib e nivolumab para tratamento de cancro | |
| IL287538A (en) | Preparations and methods for the treatment of cancer | |
| IL288003A (en) | Cancer treatment methods using chk1 inhibitors | |
| HK40059427A (en) | Administration of pd-1 inhibitors for treating skin cancer | |
| GB201918815D0 (en) | Treatment of cancer | |
| HK40069779A (en) | Multispecific agents for treatment of cancer | |
| HK40074624A (en) | Inhibition of sirp-gamma for cancer treatment | |
| HK40077564A (en) | Use of dkk-1 inhibitors for treating cancer |